Prostate Cancer Registry collecting treatment data on patients with Castrate-Resistant prostate cancer to investigate the outcomes of these treatments.

Not Applicable

Recruiting

• Conditions: Castrate-Resistant Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12616000585426
• Lead Sponsor: Walter & Eliza Hall Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-05
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 800

Inclusion Criteria

Patients eligible for enrolment onto ePAD must meet the following criteria:
- Patients of any age and any ECOG performance status
- Diagnosis of CRPC, with or without metastatic disease
- Histological or cytological confirmation of prostate cancer diagnosis and confirmation of castration-resistance
* Histological confirmation of disease is not required in the case of
PSA >50 at initial diagnosis
- No previous systemic therapy for metastatic castration resistant disease, or patients must be initiating 1st or 2nd line therapy in the mCRPC setting (i.e. patients who have yet to receive treatment for mCRPC are eligible; additionally, patients who have recently started 1st or 2nd line treatment for mCRPC are also eligible)
* First generation anti-androgens are allowed prior to enrolment

Exclusion Criteria

Exclusion criteria for ePAD include:
- Patients who have received more than two lines of therapy already
- Patients who are not eligible for treatment
(chemotherapy or targeted therapies) subsidized by the PBS

Study & Design

• Study Type: Observational
• Study Design: Not specified